Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
Net loss: US$20.9m (loss narrowed by 15% from 2Q 2023). US$0.09 loss per share (improved from US$0.38 loss in 2Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Taysha Gene Therapies EPS Beats Expectations, Revenues Fall Short Revenue missed analyst estimates by 58%. Earnings per share (EPS) exceeded analyst estimates by 9.2%. Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 7.7% from a week ago. Risk Analysis You should learn about the 3 warning signs we've spotted with Taysha Gene Therapies (including 1 which is a bit unpleasant) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target lowered by analysts at Needham & Company LLC from $7.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
TSHA
Earnings
- 8/12/24 - Beat
TSHA
Sec Filings
- 8/12/24 - Form 10-Q
- 8/12/24 - Form 8-K
- 7/5/24 - Form 144
- TSHA's page on the SEC website